Survival after active surveillance versus upfront surgery for incidental small pancreatic neuroendocrine tumours.


Journal

The British journal of surgery
ISSN: 1365-2168
Titre abrégé: Br J Surg
Pays: England
ID NLM: 0372553

Informations de publication

Date de publication:
15 07 2022
Historique:
received: 18 07 2021
revised: 07 12 2021
accepted: 16 03 2022
pubmed: 21 5 2022
medline: 22 7 2022
entrez: 20 5 2022
Statut: ppublish

Résumé

The safety of observing small non-functioning pancreatic neuroendocrine tumours (NF-Pan-NETs) remains under debate. This was a multicentre retrospective study of patients with small incidental NF-Pan-NETs. Survival of patients who underwent upfront surgery versus active surveillance was compared. The risk of death was matched with that in the healthy population. The excess hazard rate and probability of a normal lifespan (NLP) were calculated. Propensity score matching (PSM) with a 1 : 1 ratio was used to minimize the risk of selection bias. Some 222 patients (43.7 per cent) underwent upfront surgery and 285 (56.3 per cent) were observed. The excess hazard rate for the entire cohort was quantifiable as 0.04 (95 per cent c.i. 0 to 0.08) deaths per 1000 persons per year, and the NLP was 99.7 per cent. Patients in the active surveillance group were older (median age 65 versus 58 years; P < 0.001), and more often had co-morbidity (45.3 versus 24.8 per cent; P = 0.001), and smaller tumours (median 12 versus 13 mm; P < 0.001), less frequently located in the pancreatic body-tail (59.5 versus 69.6 per cent; P = 0.008, 59.3 versus 73.9 per cent; P = 0.001). Median follow-up was longer for patients who underwent upfront surgery (5.6 versus 2.7 years; P < 0.001). After PSM, 118 patients per group were included. The excess hazard rates were 0.2 and 0.9 deaths per 1000 persons per year (P = 0.020) for patients in the active surveillance and upfront surgery groups respectively. Corresponding NLPs were 99.9 and 99.5 per cent respectively (P = 0.011). Active surveillance of small incidental NF-Pan-NETs is a reasonable alternative to resection.

Sections du résumé

BACKGROUND
The safety of observing small non-functioning pancreatic neuroendocrine tumours (NF-Pan-NETs) remains under debate.
METHODS
This was a multicentre retrospective study of patients with small incidental NF-Pan-NETs. Survival of patients who underwent upfront surgery versus active surveillance was compared. The risk of death was matched with that in the healthy population. The excess hazard rate and probability of a normal lifespan (NLP) were calculated. Propensity score matching (PSM) with a 1 : 1 ratio was used to minimize the risk of selection bias.
RESULTS
Some 222 patients (43.7 per cent) underwent upfront surgery and 285 (56.3 per cent) were observed. The excess hazard rate for the entire cohort was quantifiable as 0.04 (95 per cent c.i. 0 to 0.08) deaths per 1000 persons per year, and the NLP was 99.7 per cent. Patients in the active surveillance group were older (median age 65 versus 58 years; P < 0.001), and more often had co-morbidity (45.3 versus 24.8 per cent; P = 0.001), and smaller tumours (median 12 versus 13 mm; P < 0.001), less frequently located in the pancreatic body-tail (59.5 versus 69.6 per cent; P = 0.008, 59.3 versus 73.9 per cent; P = 0.001). Median follow-up was longer for patients who underwent upfront surgery (5.6 versus 2.7 years; P < 0.001). After PSM, 118 patients per group were included. The excess hazard rates were 0.2 and 0.9 deaths per 1000 persons per year (P = 0.020) for patients in the active surveillance and upfront surgery groups respectively. Corresponding NLPs were 99.9 and 99.5 per cent respectively (P = 0.011).
CONCLUSION
Active surveillance of small incidental NF-Pan-NETs is a reasonable alternative to resection.

Identifiants

pubmed: 35595258
pii: 6589936
doi: 10.1093/bjs/znac106
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

733-738

Commentaires et corrections

Type : CommentIn

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of BJS Society Ltd. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Claudio Ricci (C)

Division of Pancreatic Surgery, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Department of Internal Medicine and Surgery (DIMEC); Alma Mater Studiorum, University of Bologna, Bologna, Italy.

Stefano Partelli (S)

Pancreatic Surgery Unit, Pancreas Translational, and Clinical Research Centre, San Raffaele Scientific Institute, Milan, Italy.
'Vita-Salute' San Raffaele University, Milan, Italy.

Luca Landoni (L)

General and Pancreatic Surgery Department, Pancreas Institute-University of Verona Hospital Trust, Verona, Italy.

Maria Rinzivillo (M)

Digestive and Liver Diseases Unit, Sant'Andrea Hospital, Rome, Italy.

Carlo Ingaldi (C)

Division of Pancreatic Surgery, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Department of Internal Medicine and Surgery (DIMEC); Alma Mater Studiorum, University of Bologna, Bologna, Italy.

Valentina Andreasi (V)

Pancreatic Surgery Unit, Pancreas Translational, and Clinical Research Centre, San Raffaele Scientific Institute, Milan, Italy.
'Vita-Salute' San Raffaele University, Milan, Italy.

Giulia Savegnago (G)

General and Pancreatic Surgery Department, Pancreas Institute-University of Verona Hospital Trust, Verona, Italy.

Francesca Muffatti (F)

Pancreatic Surgery Unit, Pancreas Translational, and Clinical Research Centre, San Raffaele Scientific Institute, Milan, Italy.
'Vita-Salute' San Raffaele University, Milan, Italy.

Michele Fontana (M)

General and Pancreatic Surgery Department, Pancreas Institute-University of Verona Hospital Trust, Verona, Italy.

Domenico Tamburrino (D)

Pancreatic Surgery Unit, Pancreas Translational, and Clinical Research Centre, San Raffaele Scientific Institute, Milan, Italy.

Giacomo Deiro (G)

General and Pancreatic Surgery Department, Pancreas Institute-University of Verona Hospital Trust, Verona, Italy.

Laura Alberici (L)

Division of Pancreatic Surgery, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Department of Internal Medicine and Surgery (DIMEC); Alma Mater Studiorum, University of Bologna, Bologna, Italy.

Davide Campana (D)

Division of Pancreatic Surgery, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Division of Oncology, IRCCS, Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy.

Francesco Panzuto (F)

Digestive and Liver Diseases Unit, Sant'Andrea Hospital, Rome, Italy.

Massimiliano Tuveri (M)

General and Pancreatic Surgery Department, Pancreas Institute-University of Verona Hospital Trust, Verona, Italy.

Claudio Bassi (C)

General and Pancreatic Surgery Department, Pancreas Institute-University of Verona Hospital Trust, Verona, Italy.

Roberto Salvia (R)

General and Pancreatic Surgery Department, Pancreas Institute-University of Verona Hospital Trust, Verona, Italy.

Massimo Falconi (M)

Pancreatic Surgery Unit, Pancreas Translational, and Clinical Research Centre, San Raffaele Scientific Institute, Milan, Italy.
'Vita-Salute' San Raffaele University, Milan, Italy.

Riccardo Casadei (R)

Division of Pancreatic Surgery, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Department of Internal Medicine and Surgery (DIMEC); Alma Mater Studiorum, University of Bologna, Bologna, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH